0.01Open0.01Pre Close0 Volume20 Open Interest5.00Strike Price0.00Turnover347.28%IV260.43%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0363Delta0.0940Gamma139.00Leverage Ratio-0.0028Theta0.0000Rho5.04Eff Leverage0.0002Vega
Reneo Pharmaceuticals Stock Discussion
$Merck & Co(MRK.US)$ to acquire EyeBio
$Biogen(BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US)$
$Novartis AG(NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
$Biogen(BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US)$
$Harmony Biosciences(HRMY.US)$ acquired Epygenix Tx
What companies will be next? 🤔
NEWS
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals and OnKure announced a merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focusing on advancing OnKure's precision medicines in oncology. The combined company is expected to have $120 million in cash resources at close, funding through 2026. OnKure's lead program, OKI-219, is in a Phase 1 clinical trial for solid tumors.
well..a kind of first green day anyway
No comment yet